Опубликована: Янв. 1, 2025
Язык: Английский
Drug Discovery Today, Год журнала: 2024, Номер 29(11), С. 104161 - 104161
Опубликована: Сен. 7, 2024
Язык: Английский
Процитировано
22
Journal of Materials Chemistry B, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
This review discusses the recent developments in copper-based nanomaterials that utilize copper-induced cell death, categorized by materials systems, while highlighting limitations of current cuproptosis related nanomaterials.
Язык: Английский
Процитировано
2
Molecular Biology Reports, Год журнала: 2025, Номер 52(1)
Опубликована: Янв. 21, 2025
Язык: Английский
Процитировано
2
Advanced Science, Год журнала: 2023, Номер 11(7)
Опубликована: Дек. 8, 2023
Abstract Endogenous essential metal ions play an important role in many life processes, especially tumor development and immune response. The approval of various metallodrugs for therapy brings more attention to the antitumor effect ions. With deepening understanding regulation mechanisms ion homeostasis vivo, breaking intracellular becomes a new means inhibit proliferation cells activate Diverse nanomedicines with loading small molecular regulators or have been developed disrupt cells, higher safety efficiency than free compounds. This comprehensive review focuses on latest progress regulation‐based including calcium (Ca 2+ ), ferrous (Fe cuprous (Cu + managanese (Mn zinc (Zn ). physiological functions processes are summarized guide design nanomedicines. Then ions‐based some efficient synergistic therapies highlighted. Finally, challenges future developments also discussed, hoping provide reference finding effective therapies.
Язык: Английский
Процитировано
37
Frontiers in Pharmacology, Год журнала: 2024, Номер 15
Опубликована: Март 8, 2024
Cancer stands as a prominent global cause of death. One the key reasons why clinical tumor chemotherapy fails is multidrug resistance (MDR). In recent decades, accumulated studies have shown how Natural Product-Derived Compounds can reverse MDR. Discovering novel potential modulators to reduce MDR by has become popular research area across globe. Numerous mainly focus on natural products including flavonoids, alkaloids, terpenoids, polyphenols and coumarins for their modulatory activity. regulating signaling pathways or relevant expressed protein gene. Here we perform deep review previous achievements, advances in development treatment This aims provide some insights study products.
Язык: Английский
Процитировано
14
European Journal of Medicinal Chemistry, Год журнала: 2024, Номер 270, С. 116387 - 116387
Опубликована: Апрель 1, 2024
Язык: Английский
Процитировано
10
Molecular Diversity, Год журнала: 2025, Номер unknown
Опубликована: Март 19, 2025
Язык: Английский
Процитировано
1
European Journal of Medicinal Chemistry, Год журнала: 2024, Номер 275, С. 116562 - 116562
Опубликована: Июнь 4, 2024
Язык: Английский
Процитировано
8
Materials Today Bio, Год журнала: 2024, Номер 26, С. 101029 - 101029
Опубликована: Март 19, 2024
Multi-drug resistance (MDR) in advanced breast cancer (ABC) is triggered by the high expression of P-glycoprotein (P-gp), which reduces intracellular concentration anti-tumor drugs, turn preventing oxidative stress damage to cytoplasmic and mitochondrial membranes. It therefore clinical relevance develop P-gp-specific targeted nanocarriers for treatment drug resistant ABC. Herein, a carrier targeting CD44 mitochondria was synthesised delivery encequidar (ER, P-gp inhibitor) paclitaxel (PTX). HT@ER/PTX nanoparticles (ER:PTX molar ratio 1:1) had excellent inhibition ability induce apoptosis MCF-7/PTX cells vitro. Furthermore, showed more efficacy than PTX (Taxol®) xenograft mouse model cells; tumor inhibitory rates Taxol® were 72.64% ± 4.41% 32.36% 4.09%, respectively. The survival tumor-bearing mice administered prolonged compared that treated with Taxol®. In addition, not only inhibited P-gp-mediated removal toxic lipid peroxidation byproducts resulting from drugs but also upregulated dynamics-related protein, fostering damage, induced activation Caspase-3 pathway. Our findings indicate co-delivery inhibitors could be practical approach treating multi-drug
Язык: Английский
Процитировано
7
Molecules, Год журнала: 2024, Номер 29(17), С. 3994 - 3994
Опубликована: Авг. 23, 2024
Drug resistance remains a critical barrier in cancer therapy, diminishing the effectiveness of chemotherapeutic, targeted, and immunotherapeutic agents. Overexpression proteins such as B-cell lymphoma 2 (Bcl-2), inhibitor apoptosis (IAPs), protein kinase B (Akt), P-glycoprotein (P-gp) various cancers leads to by inhibiting apoptosis, enhancing cell survival, expelling drugs. Although several inhibitors targeting these have been developed, their clinical use is often hampered systemic toxicity, poor bioavailability, development. Nanoparticle-based drug delivery systems present promising solution improving solubility, stability, targeted delivery. These leverage Enhanced Permeation Retention (EPR) effect accumulate tumor tissues, reducing off-target toxicity increasing therapeutic efficacy. Co-encapsulation strategies involving anticancer drugs within nanoparticles shown potential achieving coordinated pharmacokinetic pharmacodynamic profiles. This review discusses mechanisms resistance, limitations current inhibitors, advantages nanoparticle overcoming challenges. By advancing technologies, we can enhance treatment outcomes move towards more effective therapies.
Язык: Английский
Процитировано
7